ReviewSeminars in liver disease2013
Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP.
Review in Seminars in liver disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial.BMC public health · 2024Trial
- Does whey protein supplementation during resistance exercise have additional benefits for decreasing hepatic fat content?Journal of the International Society of Sports Nutrition · 2023Trial
- Genetics of MASLD: a diabetes perspective.Diabetologia · 2026Review
- Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.International journal of molecular sciences · 2026Review
- SREBP1c modulates Treg immunobiology through a phospholipid-dependent adenosine pathway.The Journal of clinical investigation · 2026Article
- Interorgan Crosstalk in MASLD: A Narrative Review.Biomedicines · 2026Review
- Sugar Shockwaves: How the Fructose-Glucose-ChREBP Pathway Hijacks Liver Metabolism.Life (Basel, Switzerland) · 2026Review
- Developing adverse outcome pathways underlying CAR activation-induced liver injuries using HepG2 spheroid model.Archives of toxicology · 2026Article
- Article
- MicroRNAs in Obesity, Insulin Resistance, and Type 2 Diabetes: Mechanistic Insights and Translational Perspectives.International journal of molecular sciences · 2026Review
- Stearoyl-CoA desaturase 1 integrates tissue-specific oncogenic pathways into a pan-cancer ferroptosis resistance program.Cell death & disease · 2026Review
- Sangyod rice extract attenuates oleic acid-induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways.Food chemistry. Molecular sciences · 2026Article
- Role of SCAP in regulation of pancreatic homeostasis, pancreatitis, and tumorigenesis.Oncogene · 2026Article
- Article
- Carbohydrate-dependent interaction between AMY1A/AMY2B copy number variation and APOA5 rs651821 associated with hypertriglyceridemia in Korean middle-aged adults.BMC nutrition · 2026Article
- Experimental Models of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of a Choline-Deficient and Cholesterol-Enriched Diet in Rats.International journal of molecular sciences · 2026Article
- Role of liver X receptors in the pathogenesis and treatment of chronic liver disease (Review).Molecular medicine reports · 2026Review
- ChREBP-mediated regulation of lipid metabolism in liver and brown adipose tissue of long-lived mice.GeroScience · 2026Article
- Effects of dietary supplementation with nopal (Opuntia ficus-indica) on productivity, egg composition, and maternal-embryonic metabolism in laying hens under a family poultry production system.Tropical animal health and production · 2026Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The liver is a central organ that controls systemic energy homeostasis and nutrient metabolism. Dietary carbohydrates and lipids, and fatty acids derived from adipose tissue are delivered to the liver, and utilized for gluconeogenesis, lipogenesis, and ketogenesis, which are tightly regulated by hormonal and neural signals. Hepatic lipogenesis is activated primarily by insulin that is secreted from the pancreas after a high-carbohydrate meal. Sterol regulatory element binding protein-1c (SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP) are major transcriptional regulators that induce key lipogenic enzymes to promote lipogenesis in the liver. Sterol regulatory element binding protein-1c is activated by insulin through complex signaling cascades that control SREBP-1c at both transcriptional and posttranslational levels. Carbohydrate-responsive element-binding protein is activated by glucose independently of insulin. Here, the authors attempt to summarize the current understanding of the molecular mechanism for the transcriptional regulation of hepatic lipogenesis, focusing on recent studies that explore the signaling pathways controlling SREBPs and ChREBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.